Ann: Investigation of Concerns around CEO Share Trading, page-96

One of the Chief Investigator for Foxfire is Professor Ricky Sharma

https://www.ucl.ac.uk/cancer/resear...iation-oncology/research-profile-ricky-sharma

Professor Ricky Sharma is Chair of Radiation Oncology at University College London and a Scientific Group Leader at the UCL Cancer Institute.  He is also an Honorary Consultant in Clinical Oncology at University College London Hospitals and the Royal Free Hospital, where he has a clinical practice in radiotherapy and chemotherapy.  He graduated in medicine from the University of Cambridge, United Kingdom. He trained in general internal medicine, medical oncology and radiation oncology and completed a PhD on DNA damage repair.  Ricky Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy.

The other Chief Investigator is Dr Harpreet Wasan

https://www.bmihealthcare.co.uk/consultants/harpreet-wasan

Dr Harpreet Wasan leads the gastrointestinal clinical research programme at Hammersmith Hospital, Imperial College London. He is on the UK National Cancer Research Institute steering committee of both the advanced colorectal cancer and upper gastrointestinal groups, as well as the inaugural chair of the West London Cancer Network.
Dr Wasan is involved in the Trial management of many CRC studies including one of the largest metastatic colorectal cancer studies in the world (COIN study), and the chief investigator (CI) in its sub-study (COIN-B), as well as a co-investigator on the largest prospective study in chemotherapy in the elderly (FOCUS-2) which reports in 2007. He is on the European working party on CRC liver metastases guidance.
In upper gastrointestinal cancer he is Co-PI and PI in the UK NRCN trials portfolio in advanced Biliary cancer and Cancer of unknown primary, with the latter two designed to be the largest studies of their kind in the world. He is a fellow of the Royal College of Physicians and the Oncology advisor to the UK Drugs and Therapeutics Bulletin (DTB) amongst many other national consultative roles.